research use only

Hydrocortisone sodium succinate Interleukins inhibitor

Name: Hydrocortisone sodium succinate
Brand: Selleck Chemicals
SKU: E0177
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0177

Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. This compound can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators.

Chemical Structure

Molecular Weight: 484.51

Jump to

Quality Control

Batch: Purity: 99.05%

99.05

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Anti-infection Antioxidant COX Histamine Receptor
Other Interleukins Inhibitors	SC144 Ossirene (AS101) Diacerein Apilimod mesylate Ac-YVAD-cmk EC330 Raleukin Diethyl phosphate Sodium Thiocyanate IQ 3

Solubility

In vitro
Batch:

DMSO : 97 mg/mL (200.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 97 mg/mL

Ethanol : 2 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	484.51	Formula	C₂₅H₃₃O₈.Na	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	125-04-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Hydrocortisone 21-hemisuccinate sodium salt			SMILES	[Na+].CC12CCC(=O)C=C1CCC3C4CCC(O)(C(=O)COC(=O)CCC([O-])=O)C4(C)CC(O)C23

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	glucocorticoid receptor IL-6 6.7 μM
References	[1] https://pubmed.ncbi.nlm.nih.gov/11411563/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07072585	NOT_YET_RECRUITING	Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma	Children's Oncology Group	2026-08-28	PHASE2; PHASE3
NCT06289673	RECRUITING	Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	2024-12-26	PHASE4
NCT07387926	RECRUITING	Acute Lymphoblastic Leukemia; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	2026-07-05	PHASE1; PHASE2
NCT07612631	RECRUITING	Alcohol Use Disorder	Rajesh Narendran	2026-06-01	EARLY_PHASE1
NCT06942039	RECRUITING	CNS Embryonal Tumor; CNS, Medulloblastoma; Atypical Teratoid Rhabdoid Tumor; Medulloblastoma, Childhood; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Pineoblastoma; Neuroblastoma; Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma; CNS Embryonal Tumor With Rhabdoid Features; CNS Embryonal Tumor, Nos	C17 Council	2025-09-23	EARLY_PHASE1
NCT06892210	RECRUITING	Chronic Obstructive Pulmonary Disease (COPD)	Copenhagen Respiratory Research	2026-03-10	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):